Vallon Pharmaceuticals
General Information | |
Business: | We are a biopharmaceutical company primarily focused on the development and commercialization of proprietary biopharmaceutical products. We are developing prescription drugs for central nervous system (CNS) disorders and our current focus is the development of drugs with lower potential for abuse than currently available drugs.
Our clinical-stage product currently under development is Abuse-Deterrent Amphetamine Immediate-Release, or ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder, or ADHD, and narcolepsy. We aim to be the first company to introduce a proprietary abuse-deterrent immediate-release dextroamphetamine drug to the market and leverage our agility, flexibility, and know-how to utilize such a position for the benefit of patients, physicians, and our community. It is estimated that over 5 million Americans abuse prescription ADHD stimulants annually. We intend to develop ADAIR for registration through the Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FDCA, approval pathway, which obviates the need for large Phase 2 and Phase 3 efficacy and safety studies.
|
Industry: | Pharmaceuticals |
Employees: | 2 |
Founded: | 2018 |
Contact Information | |
Address | Two Logan Square 100 N. 18th Street Suite 300 Philadelphia, PA 19103 |
Phone Number | (267) 207-3606 |
Web Address | https://www.vallon-pharma.com/ |
View Prospectus: | Vallon Pharmaceuticals |
Financial Information | |
Market Cap | $55.62mil |
Revenues | $0.1 mil (last 12 months) |
Net Income | $-4.22 mil (last 12 months) |
IPO Profile | |
Symbol | VLON |
Exchange | NASDAQ |
Shares (millions): | 1.7 |
Price range | $8.00 - $10.00 |
Est. $ Volume | $15.0 mil |
Manager / Joint Managers | ThinkEquity |
CO-Managers | |
Expected To Trade: | |
Status: | TBA |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |